Parallel Advisors
NPCE icon

Parallel Advisors’s Neuropace NPCE Stock Holding History

Parallel Advisors’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.13K Buy
+82
New +$1.22K ﹤0.01% 3756
2025
Q3 		– Sell
-15
Closed -$167 – 3641
2025
Q2 		$167 Sell
15
-4
-21% -$50 ﹤0.01% 3430
2025
Q1 		$234 Buy
+19
New +$238 ﹤0.01% 3357

Other funds holding NPCE

Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
SJS Investment Consulting
SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return
EverSource Wealth Advisors
EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
ORG Wealth Partners
ORG Wealth Partners Dallas, Texas $607M AUM 23.88% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Parallel Advisors's NPCE Position: Q3 2026 in Review

Parallel Advisors opened a new position in Neuropace (NPCE) in Q3 2026: 82 shares worth $1.13K. The stake represents ﹤0.01% of the portfolio and ranks #3756 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in NPCE as recently as Q2 2025.

Parallel Advisors first reported a position in NPCE in Q1 2025 and has held it in 3 quarters since. 15 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • Parallel Advisors held 82 shares of Neuropace worth $1.13K as of Q3 2026.
  • Neuropace was a new Parallel Advisors position in Q3 2026.
  • Neuropace made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3756 holding.
  • Parallel Advisors first reported a position in Neuropace in Q1 2025 and has held it in 3 quarters since.
  • 15 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.